Emergent BioSolutions Pumps Out Bulk Active Drug Product for J&J COVID Vaccine, an Industrial Info Market Brief

Johnson & Johnson's COVID-19 vaccine has become the third to receive emergency use authorization by the U.S. Food and Drug Administration (FDA). Emergent BioSolutions is busy producing the bulk active drug product for the vaccine, before it is shipped off for "fill and finish" at other plants, including those owned by CMO manufacturer Catalent. In that step, the drug product is thawed, diluted and divided into vials ready for distribution.